Medicare Rates For Hospital Outpatient Drugs Lowered To ASP+5% In 2008
Executive Summary
Medicare will reimburse drugs provided through hospital outpatient departments in 2008 at a lower Part B rate than this year, and, for the first time since the start of the average sales price methodology, lower than the rate set for products provided in physician offices
You may also be interested in...
Amgen’s Bundling Of ESAs With Neulasta and Neupogen Draws House Scrutiny
Amgen's offering of discounts to physicians and clinics for purchasing the white blood cell growth factors Neulasta and Neupogen together with the erythropoiesis-stimulation agents Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) has once again come under scrutiny, this time from the House Energy and Commerce Committee
Amgen’s Bundling Of ESAs With Neulasta and Neupogen Draws House Scrutiny
Amgen's offering of discounts to physicians and clinics for purchasing the white blood cell growth factors Neulasta and Neupogen together with the erythropoiesis-stimulation agents Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) has once again come under scrutiny, this time from the House Energy and Commerce Committee
CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted
After winning a short-term reprieve from Medicare's payment cap on radioimmunotherapies, Cell Therapeutics will focus on convincing CMS to pay for those drugs under Part B's average sales price formula